Sumitomo Mitsui Trust Group Trims AbbVie Stake

Institutional investor reduces holdings in pharmaceutical giant AbbVie by 3.6% in Q4 2025

Apr. 12, 2026 at 10:54am

Got story updates? Submit your updates here. ›

A highly detailed, cinematic close-up image of the gears, levers, and mechanisms of a sophisticated financial instrument, conveying a sense of the intricate infrastructure that powers the global financial system.An extreme close-up of the inner workings of a financial institution highlights the complex machinery that underpins the global economy.North Chicago Today

Sumitomo Mitsui Trust Group Inc., a major institutional investor, reduced its stake in AbbVie Inc. (NYSE: ABBV) by 3.6% in the fourth quarter of 2025, according to a recent 13F filing with the Securities and Exchange Commission. The fund now owns 4,102,845 shares of the pharmaceutical company's stock, valued at $937,459,000, making it AbbVie's 24th largest institutional shareholder.

Why it matters

AbbVie is a leading global biopharmaceutical company with a diverse portfolio of specialty medicines. Tracking institutional ownership and trading activity can provide insights into market sentiment and potential future performance of the stock.

The details

In its 13F filing, Sumitomo Mitsui Trust Group reported selling 153,226 shares of AbbVie during the fourth quarter. The fund now owns approximately 0.23% of AbbVie's outstanding shares. Several other major hedge funds have also recently adjusted their AbbVie holdings, with some increasing and others decreasing their positions.

  • Sumitomo Mitsui Trust Group filed its 13F report for the fourth quarter of 2025 on April 12, 2026.

The players

Sumitomo Mitsui Trust Group Inc.

A major Japanese financial services group and institutional investor.

AbbVie Inc.

A global biopharmaceutical company focused on developing specialty medicines across immunology, oncology, neuroscience, and other therapeutic areas.

Got photos? Submit your photos here. ›

The takeaway

This filing highlights the ongoing shifts in institutional ownership of AbbVie as investors monitor the company's pipeline, financial performance, and competitive landscape within the pharmaceutical industry.